EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer: Cambridge, UK Tuesday, February 4, 2025, 09:00 Hrs [IST] Astr ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...

Teliso-V (telisotuzumab vedotin) is pitching to become the first targeted cancer treatment for people with non-small cell lung cancer ... as well as a resistance mechanism that tumours can ...

in combination with partner AstraZeneca's EGFR inhibitor Tagrisso (osimertinib) in non-small cell lung cancer (NSCLC) patients with MET amplification after progression on first-line EGFR inhibitor ...

A comprehensive search was conducted using the following terms: (“EGFR-TKI” OR “VEGF-TKI” OR “Gefitinib” OR “Erlotinib” OR “Icotinib” OR “Afatinib” OR “Dacomitinib” OR “Osimertinib” OR “ALK inhibitors ...

Understanding how tumors change their metabolism to resist treatments is a growing focus in cancer research. As cancer cells adapt to therapies, their metabolism often shifts, which can help them ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more ...

Plus, with this new tool, scientists can generate new, streamlined cell lines with evolved properties, such as being optimized for growth, studying drug resistance, or bioengineered to create ...

Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related ...